ImmunoPrecise Antibodies Ltd. Stock Toronto S.E.
Stocks
IPA
CA45257F2008
Pharmaceuticals
| Market Cap | 101M 70.67M 63.14M 58.91M 53.51M 6.84B 102M 708M 277M 3.48B 265M 260M 11.18B | P/E 2027 * |
-5.11x | P/E 2028 * | -5.92x |
|---|---|---|---|---|---|
| Enterprise Value | 101M 70.67M 63.14M 58.91M 53.51M 6.84B 102M 708M 277M 3.48B 265M 260M 11.18B | EV / Sales 2027 * |
5.74x | EV / Sales 2028 * | 4.67x |
| Free-Float |
90.86% | Yield 2027 * |
-
| Yield 2028 * | - |
Last Transcript: ImmunoPrecise Antibodies Ltd.
| 1 day | +0.78% |
| Manager | Title | Age | Since |
|---|---|---|---|
Jennifer Bath
CEO | Chief Executive Officer | - | 21/02/2018 |
Richard Areglado
DFI | Director of Finance/CFO | 62 | 20/10/2025 |
Hyfte Van
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Jennifer Bath
BRD | Director/Board Member | - | 24/05/2018 |
Dirk Witters
CHM | Chairman | - | - |
Jonathan Lieber
BRD | Director/Board Member | 56 | 07/07/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.78% | -7.67% | - | - | 70.67M | |
| +2.70% | +2.73% | +40.91% | +110.31% | 1,060B | |
| +1.44% | -2.38% | +36.83% | +63.95% | 623B | |
| +1.75% | +3.73% | +16.55% | +83.05% | 480B | |
| +0.60% | -1.73% | +62.98% | +37.46% | 352B | |
| -1.81% | +1.49% | +21.59% | +41.20% | 345B | |
| -1.19% | +0.51% | +11.42% | +34.64% | 274B | |
| -0.95% | -1.71% | -5.56% | +11.18% | 249B | |
| +2.60% | -2.00% | +39.77% | +54.44% | 223B | |
| +1.82% | -1.48% | +25.75% | +96.48% | 182B | |
| Average | +0.28% | -0.48% | +27.80% | +59.19% | 420.89B | |
| Weighted average by Cap. | -0.06% | +0.04% | +31.46% | +70.21% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 17.56M 12.31M 11M 10.26M 9.32M 1.19B 17.69M 123M 48.19M 606M 46.22M 45.22M 1.95B | 21.59M 15.14M 13.52M 12.62M 11.46M 1.46B 21.75M 152M 59.24M 745M 56.83M 55.6M 2.39B |
| Net income | -19.36M -13.58M -12.13M -11.32M -10.28M -1.31B -19.5M -136M -53.13M -668M -50.97M -49.87M -2.15B | -17.23M -12.08M -10.8M -10.07M -9.15M -1.17B -17.36M -121M -47.29M -594M -45.37M -44.38M -1.91B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
